IPF patients treated with IFN-γ-1b had significantly decreased CXCL1 BAL levels after 12 months of treatment, suggesting that IFN-γ may be an essential mediator counterbalancing angiogenesis during IPF [242]. This evidence concerns the gene IFNG and idiopathic pulmonary fibrosis.